Review of select causes of drug-induced AKI

Expert Review of Clinical Pharmacology

Volumn 8, Issue 4, 2015, Pages 367-371

  Perazella, Mark A ^a   Luciano, Randy L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute interstitial nephritis; acute kidney injury; anti angiogenesis; drugs; interferon; methotrexate; nonsteroidal anti inflammatory drugs; proton pump inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; CORTICOSTEROID; DIURETIC AGENT; FOLINIC ACID; GAMMA GLUTAMYL HYDROLASE; INFUSION FLUID; INTERFERON; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ACUTE KIDNEY FAILURE; CRYSTALLINE INDUCED ACUTE KIDNEY FAILURE; DRUG INDUCED ACUTE KIDNEY FAILURE; DRUG INDUCED DISEASE; FOCAL GLOMERULOSCLEROSIS; HEMODYNAMIC ACUTE KIDNEY FAILURE; HUMAN; INTERSTITIAL NEPHRITIS; MINIMAL CHANGE DISEASE; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; ACUTE KIDNEY INJURY; CHEMICALLY INDUCED; RISK FACTOR; THROMBOSIS;

ACUTE KIDNEY INJURY; HUMANS; RISK FACTORS; THROMBOSIS;

EID: 84933533555     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1045489     Document Type: Review

References (26)

1. Perazella MA. Renal vulnerability to drug toxicity. Clin J Am Soc Nephrol 2009;4(7):1275-83
2. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001;111(1):64-7
3. Eras J, Perazella MA. NSAIDs and the kidney revisited: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 2001;321(3):181-90
4. Balasubramanian G, Al-Aly Z, Moiz A, et al. Early nephrologist involvement in hospital-acquired acute kidney injury: a pilot study. Am J Kidney Dis 2011;57(2):228-34
5. Coca SG, Garg AX, Swaminathan M, et al. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 2013;28(11):2787-99
6. Perazella MA, Coca SG. Three feasible strategies to minimize kidney injury in 'incipient AKI'. Nat Rev Nephrol 2013;9(8):484-90
7. Gurevich V, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122:322-8
8. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol 2015. [Epub ahead of print]
9. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358(11):1129-36
10. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
11. Zhu X, Wu S, Dahut WL, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49:186-93
12. Izzedine H, Escudier B, Lhomme L, et al. Anti-VEGF associated kidney diseases: a 8-year monocentric observational study. Medicine 2014;93(24):333-9
13. Markowitz GS, Nasr SH, Stokes MB, et al. Treatment with interferon-alpha, -beta, or - gamma is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5:607-15
14. Feldman D, Hoar RM, Niemann WH, et al. Tubuloreticular inclusions in placental chorionic villi of rhesus monkeys after maternal treatment with interferon. Am J Obstet Gynecol 1986;155:413-24
15. Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011;22:2129-37
16. Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int 2015;87(2):332-42
17. Sand TE, Jacobsen S. Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 1981;19(6):453-6
18. Luciano RL, Perazella MA. Crystalline-induced kidney disease: a case for urine microscopy. Clin Kidney J 2015;8(2):131-6
19. Perazella MA. Crystal-induced acute renal failure. Am J Med 1999;106(4):459-65
20. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Exp Opin Drug Safety 2008;7(2):147-58
21. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Sem Nephrol 2010;30(6):570-81
22. Bertram A, Ivanyi P, Hafer C, et al. High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy? Ann Hematol 2014;93(6):1053-5
23. Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010;6(8):461-70
24. Muriithi AK, Leung N, Valeri AM, et al. Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2015;87(2):458-64
25. Blank ML, Parkin L, Paul C, et al. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int 2014;86(4):837-44
26. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007;68(2):65-72